Immunome (IMNM) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)
Immunome (IMNM) Net Income towards Common Stockholders Growth (1y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-129.68% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-290.15% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Immunome |
2.12 Bn |
1.54 Bn |
- |
-32.92% |
| Date | Value |
|---|
| Mar 31, 2026 |
-32.92% |
| Dec 31, 2025 |
12.18% |
| Sep 30, 2025 |
-19.03% |
| Jun 30, 2025 |
-16.17% |
| Mar 31, 2025 |
66.26% |
| Dec 31, 2024 |
10.43% |
| Sep 30, 2024 |
-1,062.76% |
| Jun 30, 2024 |
-593.04% |
| Mar 31, 2024 |
-2,859.05% |
| Dec 31, 2023 |
-1,089.75% |
| Sep 30, 2023 |
52.54% |
| Jun 30, 2023 |
35.32% |
| Mar 31, 2023 |
61.64% |
| Dec 31, 2022 |
0.84% |
| Sep 30, 2022 |
-18.59% |
| Jun 30, 2022 |
-55.51% |
| Mar 31, 2022 |
-199.05% |
| Dec 31, 2021 |
-92.78% |
| Sep 30, 2021 |
-173.95% |
| Jun 30, 2021 |
-111.42% |
